Companies › Zydus Therapeutics
2 active drug programs in 6 registered trials: 3 Phase 3, 2 Phase 1, 1 Phase 2; Neurology, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Saroglitazar Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist | PPARA, PPARG | Phase 3 | Primary Biliary Cholangitis; Hepatic Impairment; Cholestatic Liver Disease | Dec 2026 |
| Usnoflast | – | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05045482 | Saroglitazar | Phase 1 | Hepatic Impairment | Gastroenterology | Dec 2026 |
| NCT06825559 | Saroglitazar | Phase 1 | Cholestatic Liver Disease | Gastroenterology | Dec 2026 |
| NCT06427395 | Saroglitazar | Phase 3 | Primary Biliary Cholangitis | Gastroenterology | Apr 2027 |
| NCT07023835 | Usnoflast | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | Neurology | Mar 2028 |
| NCT07424677 | Saroglitazar | Phase 3 | Primary Biliary Cholangitis | Gastroenterology | Jul 2028 |
| NCT07216235 | Saroglitazar | Phase 3 | Primary Biliary Cholangitis | Gastroenterology | Nov 2032 |
RDC Clinical Inventiva Pharma Ipsen Kowa Company Flare Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Dong Wha Pharmaceutical
Inventiva Pharma Minoryx Therapeutics Shin Poong Pharmaceutical GRIN Therapeutics Larimar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.